Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:activities |
serotonin reuptake inhibitor
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:Allergan
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-0729
|
| gptkbp:ingredients |
C19 H22 N2 O2
|
| gptkbp:invention |
gptkb:Allergan
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
treatment of depression
|
| gptkbp:manager |
oral
|
| gptkbp:side_effect |
dizziness
nausea insomnia dry mouth |
| gptkbp:targets |
CY P2 D6 enzyme
|
| gptkbp:weight |
310.39 g/mol
|
| gptkbp:year_created |
gptkb:2015
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
4
|